Page last updated: 2024-10-15

neopterin

Cross-References

ID SourceID
PubMed CID135398721
SCHEMBL ID59519
MeSH IDM0029376

Synonyms (45)

Synonym
SMP1_000327
2-amino-4-hydroxy-6-(1,2,3-trihydroxypropyl)pteridine
4(8h)-pteridinone, 2-amino-6-[(1s,2r)-1,2,3-trihydroxypropyl]-
1,2,3-proanetriol
2-amino-6-((1s,2r)-1,2,3-trihydroxypropyl-4(8h)-pteridone
[s-(r*,s*)]-2-amino-6-(1,2,3-trihydroxypropyl)-1h-pteridin-4-one
[s-(r*,s*)]-2-amino-6-(1,2,3-trihydroxypropyl)-1h-pteridin-4-on
[s-(r*,s*)]-2-amino-6-(1,2,3-trihydroxypropyl)-1h-pteridine-4-one
C05926
d-erythro-neopterin
neopterin ,
6-d-erythro-neopterin
d-neopterin
6-(d-erythro-1,2,3-trihydroxypropyl)pterin
l-neopterin
d-(+)-neopterin, >=97.5% (sum of enantiomers, hplc)
2-amino-6-[(1s,2r)-1,2,3-trihydroxypropyl]-1h-pteridin-4-one
2-amino-6-[(1s,2r)-1,2,3-trihydroxypropyl]-4(3h)-pteridinone
2-amino-6-[(1s,2r)-1,2,3-trihydroxypropyl]-3,4-dihydropteridin-4-one
(1s,2r)-1-(2-amino-4-hydroxypteridin-6-yl)propane-1,2,3-triol
neopterin d-erythro-form
unii-9pld60n7so
(s-(r*,s*))-2-amino-6-(1,2,3-trihydroxypropyl)-1h-pteridin-4-one
einecs 217-924-7
9pld60n7so ,
(+)-neopterin
neopterin d-erythro-form [mi]
neopterin [mi]
4(3h)-pteridinone, 2-amino-6-((1s,2r)-1,2,3-trihydroxypropyl)-
SCHEMBL59519
AKOS024285557
(d-erythro-1,2,3-trihydroxypropyl)-pterin
(d)-(+)-neopterin
4(3h)-pteridinone, 2-amino-6-[(1s,2r)-1,2,3-trihydroxypropyl]-
BMQYVXCPAOLZOK-XINAWCOVSA-N
AKOS024458275
CS-W020795
HY-W040055
2-amino-6-[(1s,2r)-1,2,3-trihydroxypropyl]pteridin-4(3h)-one
2-amino-6-((1s,2r)-1,2,3-trihydroxypropyl)pteridin-4(3h)-one
DB15050
Q908292
AS-56644
2-amino-6-[(1s,2r)-1,2,3-trihydroxypropyl]-3h-pteridin-4-one
DTXSID90862811

Research Excerpts

Overview

Neopterin is an inflammatory biomarker which is released as a response to macrophage activation. Neopterin has prognostic value in cardiovascular diseases but its prognostic role in cerebrovascular diseases is not as clear.

ExcerptReference
"Neopterin is an inflammatory marker that is found to have prognostic value in cardiovascular diseases but its prognostic role in cerebrovascular diseases is not as clear. "( Serum neopterin levels and their role in the prognosis of patients with ischemic stroke: A systematic review and meta-analysis.
Cao, L; Meng, LL, 2021
)
"Neopterin is an inflammatory biomarker which is released as a response to macrophage activation."( Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level.
Amralla, MT; Dogheim, GM; Werida, RH, 2022
)
"Neopterin (NEO) is a marker of immune stimulation. "( Elevated neopterin in tuberculosis and co-infection with HIV and the effect of treatment: A systematic review, meta-analysis, and meta-regression.
Rezaei, N; Saghazadeh, A, 2022
)
"Neopterin is a biomarker of cell-mediated immune responses to intracellular infections."( Neopterin Levels in Bonobos Vary Seasonally and Reflect Symptomatic Respiratory Infections.
Behringer, V; Deimel, C; Fruth, B; Kreyer, M, 2023
)
"Neopterin is a macrophage activation marker produced by monocytes and macrophages following activation by interferon-gamma (IFN-γ)."( Inflammatory markers and neopterin levels in relation to mild COVID-19.
Karabulut, A; Şahin, M, 2023
)
"Neopterin is a biomarker for inflammation produced by macrophages."( Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis.
Babarczy, K; Galla, Z; Maróti, Z; Polyák, H; Pukoli, D; Rajda, C; Vécsei, L, 2020
)
"Neopterin is a cellular immunity biochemical marker. "( Assessment of neopterin level and severity in lichen planus patients treated with narrow-band ultraviolet B.
Khattab, FM; Samir, MA, 2020
)
"Neopterin is a surrogate marker for viral inflammation, and its production by macrophages is driven by interferon-γ."( Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19.
Adolph, TE; Bellmann-Weiler, R; Effenberger, M; Enrich, B; Fritsche, G; Grabherr, F; Mayr, L; Moschen, A; Müller, T; Pedrini, A; Reider, S; Scholl-Bürgi, S; Schwärzler, J; Tilg, H; Weiss, G; Wildner, S, 2021
)
"Neopterin is an important marker of cellular inflammation."( Fecal neopterin level determination: can be a useful screening test for colorectal polyps?
Kilciler, AG; Kutluana, U; Mizrak, S, 2021
)
"Neopterin (NPT) is a member of pteridines group, synthesized by macrophages when stimulated by interferon gamma (INF-γ). "( The potential role of neopterin in Covid-19: a new perspective.
Al-Gareeb, AI; Al-Kuraishy, HM; Alzahrani, KJ; Batiha, GE; Cruz-Martins, N, 2021
)
"Neopterin is a pyrazino-pyrimidine compound that belongs to the pteridine group. "( Neopterin as a marker of cellular immunological response.
Bulska, M; Michalak, Ł; Strząbała, K; Szcześniak, P, 2017
)
"Neopterin is an activation marker for monocytes/macrophages. "( Neopterin and Cardiovascular Events Following Coronary Stent Implantation in Patients with Stable Angina Pectoris.
Nakagawa, M; Naruko, T; Ohsawa, M; Shirai, N; Sugioka, K; Ueda, M; Yoshiyama, M; Yoshiyama, T, 2018
)
"Neopterin is a pteridine that is produced following activation of human macrophages upon stimulation with the cytokine interferon-gamma. "( Serum neopterin levels in women with preeclampsia: a systematic review.
Daskalakis, G; Karampetsou, N; Papantoniou, N; Pergialiotis, V; Thomakos, N; Zoumpourlis, P, 2018
)
"Neopterin is an important marker of cellular inflammation."( Can neopterin be a useful immune biomarker for differentiating gastric intestinal metaplasia and gastric atrophy from non-atrophic non-metaplastic chronic gastritis?
Dilli, U; Kilciler, AG; Kutluana, U; Mizrak, S, 2019
)
"Neopterin is a marker of macrophage activation that has exhibited high plasma levels in atherosclerotic diseases including coronary heart disease and critical limb ischemia. "( Neopterin: a potential marker in chronic peripheral arterial disease.
Anzaldi, M; Candido, S; Di Marco, R; Fiore, V; Mangano, K; Neri, S; Quattrocchi, C; Signorelli, SS, 2013
)
"Neopterin is a marker, belonging to the class of pteridines, which is associated with cell-mediated immunity."( Comparative analysis of gingival crevicular fluid neopterin levels in health and periodontal disease: a biochemical study.
Arjunkumar, R; Arunachalam, L; Jayakumar, P; Sudhakar, U; Suresh, S; Virupapuram, P,
)
"Neopterin is a good indicator of cellular immunity, and we evaluated serum levels of neopterin in patients with ADHD."( Increased levels of serum neopterin in attention deficit/hyperactivity disorder (ADHD).
Alisik, M; Ceylan, MF; Erel, O; Ergin, M; Goker, Z; Guney, E; Karaca Kara, F; Senses Dinc, G; Uneri, OS, 2014
)
"Neopterin is a pteridine derivative secreted by activated macrophages. "( Association of circulating levels of neopterin with non-culprit plaque vulnerability in CAD patients an angiogram, optical coherent tomography and intravascular ultrasound study.
He, J; Sun, Y; Tian, J; Wang, C; Xie, Z; Yu, B, 2015
)
"Neopterin is a novel, independent predictor of the development of depression 6 months after stroke."( Elevated Serum Levels of Neopterin at Admission Predicts Depression After Acute Ischemic Stroke: a 6-Month Follow-Up Study.
Li, WG; Shi, JP; Tang, CZ; Wang, WS; Zhang, YL, 2016
)
"Neopterin is a novel marker of immune activation produced mainly by activated macrophages."( Increased plasma neopterin levels are associated with reduced endothelial function and arterial elasticity in hypertension.
Chen, L; Tao, J; Tong, XZ; Xia, WH; Xie, WL; Yu, BB; Zhang, B; Zhang, YY, 2016
)
"Neopterin is an unconjugated pteridine that is secreted in large quantities by activated macrophages and can be used as a clinical marker of activated cellular immunity and oxidative stress. "( Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity.
Adekitan, D; Buckley, D; McHugh, PC; Strydom, A; Zis, P, 2017
)
"Neopterin is an inflammatory biomarker previously shown in CSF of stage 2 but not stage 1 patients."( Metabolomics Identifies Multiple Candidate Biomarkers to Diagnose and Stage Human African Trypanosomiasis.
Barrett, MP; Biéler, S; Bisser, S; Cattanach, AM; Courtioux, B; Daly, R; Ndung'u, JM; Vincent, IM, 2016
)
"Neopterin (NP) is a monocyte/macrophage activation marker produced by macrophages in response to interferon-gamma secreted by activated T-lymphocytes."( Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Demirdogen, E; Ege, E; Karadag, M; Oral, AY; Oral, HB; Ursavaş, A, 2008
)
"Neopterin is a marker of monocyte/macrophage activity. "( Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a.
Dijkgraaf, MG; Forestier, N; Gelderblom, HC; Jansen, PL; Mcnair, L; Purdy, S; Reesink, HW; Weegink, CJ; Zeuzem, S, 2008
)
"CSF neopterin is a useful marker of inflammation in a broad range of acute and chronic CNS disorders, and is a significantly more sensitive marker of inflammation than CSF pleocytosis."( Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation.
Brilot, F; Dale, RC; Earl, J; Fagan, E, 2009
)
"Neopterin is an immunological marker of cellular immune activation. "( Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
Akar, A; Akgul, EO; Erbil, K; Kilic, S; Koc, E; Kurt, Y; Kurumlu, Z; Tunca, M, 2009
)
"Neopterin is an independent predictor of all-cause and cardiovascular mortality in individuals with or without stable coronary artery disease."( Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study.
Boehm, BO; Fuchs, D; Grammer, TB; Maerz, W; Winkelmann, BR, 2009
)
"Neopterin seems to be a differential biomarker for malignant and benign thyroid disorders."( Is neopterin level a predictive and differential biomarker in patients with thyroid disorders?
Azili, C; Baydar, T; Dikmen, K; Girgin, G; Sahin, TT; Sipahi, H; Taneri, F; Yuksel, O, 2009
)
"Neopterin is an immunological marker of cellular immune activation, which is secreted by monocytes/macrophages as a result of interferon-gamma (IFN-gamma) secretion by activated T lymphocytes."( Is there any relationship between serum and urine neopterin and serum interferon-gamma levels in the activity of Behcet's disease?
Akkaya, VB; Basak, PY; Ceyhan, AM; Erturan, I; Ozturk, O, 2009
)
"Neopterin is an activation marker for monocytes/macrophages, and circulating levels of neopterin are elevated in patients with coronary complex lesions in unstable angina pectoris. "( Elevated levels of neopterin are associated with carotid plaques with complex morphology in patients with stable angina pectoris.
Becker, AE; Ehara, S; Haze, K; Hozumi, T; Ikura, Y; Itoh, A; Kitabayashi, C; Matsumura, Y; Nakagawa, M; Naruko, T; Shirai, N; Sugioka, K; Ueda, M; Ujino, K; Yoshiyama, M, 2010
)
"Neopterin (NT) is a compound of low molecule-based pteridine. "( The value of neopterin and procalcitonin in patients with sepsis.
Aliyazicioglu, Y; Coban, AY; Esen, S; Leblebicioglu, H; Tanyel, E; Tasdelen Fisgin, N; Ulger, F; Zivalioglu, M, 2010
)
"Neopterin is a diagnostic or a prognostic biomarker for several pathologies including renal diseases. "( Evaluation of neopterin levels in patients undergoing hemodialysis.
Asci, A; Baydar, T; Cetinkaya, R; Dolgun, A; Sahin, G, 2010
)
"Neopterin is a protein produced by monocytes/macrophages. "( Sublingual immunotherapy may affect serum neopterin: preliminary findings.
Ciprandi, G; De Amici, M; Fuchs, D; Marseglia, G, 2010
)
"Neopterin is a biomarker for immune activation, SLIT may affect serum neopterin probably as a consequence of Treg response to SLIT."( Sublingual immunotherapy may affect serum neopterin: preliminary findings.
Ciprandi, G; De Amici, M; Fuchs, D; Marseglia, G, 2010
)
"Neopterin is a marker of cytotoxic lymphocytes T activities, it is produced by monocytes/macrophages stimulated with IFNgamma."( [Neopterin in serum and cerebrospinal fluid in Lyme disease].
Biesiada, G; Czepiel, J; Garlicki, A; Mach, T, 2009
)
"Neopterin is a valuable biomarker of cellular immunity associated with various pathological situations such as viral and bacterial infections, autoimmune, cardiovascular, neurodegenerative and malignant disorders. "( Production and analytical characterization of neopterin immunoreagents for biosensor developments.
Cernoch, I; Franek, M; Schleicher, E, 2011
)
"neopterin is a monocyte/macrophage-derived immune activation marker and its levels increase with age. "( IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults.
Fedarko, NS; Hughes, J; Jain, A; Leng, SX; Li, H; Matteini, A; Tian, X; Walston, JD, 2011
)
"Neopterin is a reliable indicator for interferon-γ (IFN-γ) which was identified as the only cytokine that induces significant production of neopterin."( Psychobiological aspects of somatization syndromes: contributions of inflammatory cytokines and neopterin.
Euteneuer, F; Hennings, A; Rief, W; Riemer, S; Schwarz, MJ; Selberdinger, V; Stapf, T, 2012
)
"Neopterin is a catabolic product of guanosine triphosphate, a purine nucleotide. "( Portable potentiostatic sensor integrated with neopterin-imprinted poly(ethylene-co-vinyl alcohol)-based electrode.
Chen, YL; Hsieh, CH; Huang, CY; Juang, YZ; Lee, MH; Lin, CF; Lin, HY; Liu, BD; Tsai, HH, 2011
)
"Neopterin (NEO) is a marker of celullar immunity, and oxidative stress, mainly produced by activated macrophages."( Neopterin: a promising marker for the inflammation in polycystic ovary syndrome.
Alanbay, I; Coksuer, H; Karasahin, KE; Mutlu Ercan, C; Ozturk, O; Sakinci, M; Yaman, H, 2012
)
"Neopterin is an acknowledged marker of immunostimulation."( Neopterin as a marker of immunostimulation: an investigation in anaesthetic workplaces.
Amann, A; Fuchs, D; Gruber, G; Hoffmann, G; Keller, C; Lirk, P; Rieder, J; Schobersberger, W, 2002
)
"Neopterin is an activation marker of macrophages. "( [Serum and bronchoalveolar lavage fluid neopterin levels in patients with bronchial asthma].
Jankowska, R; Krasnowska, M; Passowicz-Muszyńska, E; Piesiak, P, 2003
)
"Neopterin is a pteridine, which is produced by monocytes/macrophages upon stimulation with the type 1 T cell-derived cytokine interferon-gamma."( Association of increased neopterin production with decreased humoral immunity in the elderly.
Asch, E; Berger, P; Fuchs, D; Grubeck-Loebenstein, B; Hainz, U; Jenewein, B; Murr, C; Saurwein-Teissl, M, 2003
)
"Neopterin is a biochemical marker of activated cell-mediated immune response which increases in pathological conditions associated with cellular immune activation as well as in pregnancy where cellular immune response is predominant. "( Urinary neopterin levels in the different stages of pregnancy.
Akgül, EO; Bayram, M; Boyunağa, H; Erbil, MK; Keleş, H; Ozer, G; Sağsöz, N; Yücel, A, 2005
)
"Neopterin is a sensitive marker for diseases involving increased activity of the cellular immune system in humans. "( Mechanism of neopterin-induced myocardial dysfunction in the isolated perfused rat heart.
Balogh, A; Balogh, D; Fuchs, D; Margreiter, J; Mittermayr, M; Schlager, A; Schobersberger, W, 2005
)
"Neopterin is an early, sensitive and non-specific marker of cellular immunity. "( The value of increased neopterin levels in reducing transfusion-transmitted virus infections: detection of a donation from a HBsAg positive chronic carrier by screening of neopterin in Turkish blood donors.
Hascelik, G; Inci Fisenk, B; Ozcebe, OI; Us, D, 2005
)
"Neopterin is an indicator of systemic immune activation in metastatic cancer and is increased after systemic IL-2 administration."( Neopterin in renal cell carcinoma: inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin.
Melichar, B; Melicharová, K; Solichová, D; Svobodová, I,
)
"Neopterin is a marker of cell-mediated immunity, and it has been demonstrated that neopterin levels of various body fluids could be elevated in tuberculosis. "( The diagnostic values of serum, pleural fluid and urine neopterin measurements in tuberculous pleurisy.
Akgul, OE; Bilgic, H; Cakir, E; Ciftci, F; Deniz, O; Ekiz, K; Erbil, K; Gumus, S; Ozcan, O; Tozkoparan, E; Yaman, H, 2005
)
"Neopterin is a low-molecular mass substance synthesized from guanosine triphosphate (GTP) in monocytes/macrophages due to IFNgamma stimulation. "( [Role of neopterin in clinical diagnostics].
Galicka-Latała, D; Kuśnierz-Cabala, B; Naskalski, JW, 2005
)
"Neopterin is a pteridine derivative, released from macrophages upon stimulation with pro-inflammatory cytokine interferon-gamma."( Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin.
Blasko, I; Falkensammer, G; Fuchs, D; Griesmacher, A; Kemmler, G; Knaus, G; Marksteiner, J; Weiss, E; Winkler, C; Würzner, R, 2007
)
"Neopterin is a pyrazino-pyrimidine compound, and is known to be a marker associated with cell-mediated immunity in various diseases. "( The clinical significance of serum and urinary neopterin levels in several renal diseases.
Joo, KJ; Jung, SS; Kim, H; Lee, KB; Lhee, HY, 2006
)
"Neopterin is a bypass product in the synthesis of tetrahydrobiopterin, which is a cofactor of NO synthase."( Nitric oxide and neopterin in bipolar affective disorder.
Fekkes, D; Hoekstra, R; Loonen, AJ; Pepplinkhuizen, L; Tuinier, S; Verhoeven, WM, 2006
)
"Neopterin is an indicator of systemic immune activation, and increased neopterin concentrations have been associated with poor prognosis in a wide range of malignant tumors."( Urinary neopterin in patients with liver tumors.
Melichar, B; Melicharová, K; Solichová, D; Svobodová, I; Urbánek, L; Veselý, P,
)
"Neopterin is an independent prognostic indicator in patients with liver tumors along with Bengtsson stage, presence of extrahepatic disease, primary site and peripheral blood leukocyte count."( Urinary neopterin in patients with liver tumors.
Melichar, B; Melicharová, K; Solichová, D; Svobodová, I; Urbánek, L; Veselý, P,
)
"Neopterin is an important parameter showing cell mediated immunity activation. "( [The role of serum neopterin level in the evaluation of activation and response to treatment in the patients with pulmonary tuberculosis].
Bukan, N; Capan, N; Ciftçi, B; Erdoğan, Y; Güler, M; Hüddam, D; Unsal, E, 2006
)
"Neopterin is an immune activation marker for the cell-mediated immune response."( Increased amyloid beta protein levels in children and adolescents with Down syndrome.
Capone, G; Freedland, RL; Jewell, A; Mehta, PD, 2007
)
"Neopterin is an independent prognostic factor for the outcome of disease, and well suited to estimate the degree of immune activation in vivo and the responsiveness of immunocompetent cells to stimulation in vitro."( Indoleamine-2, 3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infection.
Bellmann-Weiler, R; Fuchs, D; Garimorth, K; Schroecksnadel, K; Weiss, G; Zangerle, R, 2007
)
"Neopterin is a soluble marker of monocyte activation, and elevated levels are of prognostic value in patients with stable coronary artery disease."( Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A, 2007
)
"Neopterin is an immunologic marker for the activation of the cell-mediated immune system and it is found to be elevated in autoimmune diseases. "( Urinary neopterin levels in uveitis: is it a new activity marker?
Akgul, EO; Bayraktar, MZ; Durukan, AH; Hurmeric, V; Kilic, S,
)
"Neopterin is a marker of inflammation and of immune system activation, it is synthesized by macrophages, that, once activated, release this substance."( The role of neopterin in cardiovascular disease.
Chiariello, M; Cirillo, P; De Rosa, S; Maietta, P; Musto D'Amore, S; Pacileo, M; Petrillo, G; Sasso, L; Spagnuolo, R; Ucci, G, 2007
)
"Neopterin is a well-established marker of macrophage activation. "( Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
Fuchs, D; Gisslén, M; Hagberg, L; Price, RW; Spudich, S; Yilmaz, A, 2008
)
"Neopterin is a predictive biochemical marker of cell-mediated immune activation and elevated levels of neopterin are detected in body fluids of patients with immune-related diseases."( Neopterin as a marker for immune system activation in coal workers' pneumoconiosis.
Durucu, M; Karakaya, A; Ulker, OC; Yucesoy, B, 2007
)
"Neopterin seems to be an indicator of metastatic cancer rather than a marker for local cancer."( Serum neopterin levels in patients with breast cancer.
Aslan, S; Cetin, A; Coskun, U; Gunel, N; Pasaoglu, H; Yildirim, Y, 2008
)
"Neopterin is an 2-amino-4-hydroxypteridine derivative and a precursor of biopterin, which is derived from guanosine triphosphate. "( Effect of 5,6,7,8-tetrahydroneopterin on the bovine endothelial cell injury induced by cumene hydroperoxide.
Icho, T; Kajiwara, Y; Kojima, S; Kubota, K; Kurobane, T; Yoshimura, M, 1995
)
"Neopterin is a pteridine produced by human mononuclear phagocytes, usually in response to interferon-gamma (IFN-gamma) stimulation. "( Neopterin production by HIV-1-infected mononuclear phagocytes.
Dukes, CS; Matthews, TJ; Rivadeneira, ED; Weinberg, JB, 1994
)
"Neopterin is a pteridine molecule released by immune activated monocytes. "( Neopterin release by myeloid leukaemic cells can be synergistically augmented by 1,25-dihydroxyvitamin D3 in combination with gamma interferon or granulocyte-macrophage colony stimulating factor.
Coldwell, RD; Kelsey, SM; Makin, HL; Newland, AC; Syndercombe-Court, D, 1994
)
"Neopterin is an intermediate in the pathway of pteridines released in vitro from non proliferating activated cells such as macrophages stimulated with interferons. "( Serum neopterin levels in haematological malignancies.
Caenazzo, A; Dazzi, F; Girolami, A; Pietrogrande, F; Sartori, D; Sgarabotto, D; Vattamattathil, KP,
)
"Neopterin was shown to be an independent indicator for clinical activity."( The role of neopterin in assessing disease activity in Crohn's disease: classification and regression trees.
Judmaier, G; Meyersbach, P; Reibnegger, G; Wachter, H; Weiss, G, 1993
)
"Neopterin is a marker of cell-mediated immunostimulation, and may be a helpful marker in monitoring cancer patients."( [Amines and pteridines].
Chihara, T; Hibiya, M; Ito, S; Nagatsu, T; Shimpo, K, 1996
)
"Neopterin seems to be a more sensitive indicator of intrathecal T-cell response and inflammatory reaction than beta 2M."( Intrathecal production of neopterin and beta 2 microglobulin in tick-borne encephalitis (TBE) compared to meningoencephalitis of other etiology.
Forsgren, M; Günther, G; Haglund, M; Lindquist, L; Sköldenberg, B, 1996
)
"Neopterin is a sensitive marker of macrophage activity, and elevated urine excretion has been observed in viral and bacterial infections. "( [Role of the immune parameter neopterin in adnexitis].
Dapunt, O; Fuchs, D; Marth, C; Wachter, H; Windbichler, G; Zeimet, AG, 1996
)
"Neopterin is a biochemical marker for the activation of the cell-mediated immune system. "( Neopterin, beta 2-microglobulin, and acute phase proteins in HIV-1-seropositive and -seronegative Zambian patients with tuberculosis.
Dierich, MP; Elliott, AM; Fuchs, D; Hosp, M; Luo, N; McAdam, KP; Mwinga, AG; Pobee, JO; Raynes, JG; Wachter, H; Zangerle, R, 1997
)
"Neopterin, which is a by-product of the guanosine triphosphate-biopterin pathway, is a marker for those activated macrophages."( Increased neopterin in patients with chronic and acute coronary syndromes.
Eber, B; Esterbauer, H; Fruhwald, FM; Halwachs, G; Klein, W; Schumacher, M; Tatzber, F; Watzinger, N; Wilders-Truschnig, M; Zweiker, R, 1997
)
"Neopterin is a clinically valuable marker for monitoring activation of macrophages by gamma-interferon and thus reflects the TH-1 immune response."( Prolonged macrophage activation and persistent anaemia in children with complicated malaria.
Biemba, G; Gordeuk, VR; Mabeza, GF; Thuma, PE; Weiss, G, 1998
)
"Neopterin is a sensitive indicator for cellular immune activation. "( Neopterin concentrations in cerebrospinal fluid and serum as an aid in differentiating central nervous system and peripheral infections in children.
Aigner, RM; Berghold, A; Franthal, W; Füger, GF; Millner, MM; Reibnegger, G; Thalhammer, GH, 1998
)
"Neopterin is a marker for activation of the immune system. "( Neopterin: biochemistry and clinical usefulness.
Andert, SE; Müller, MM, 1995
)
"Neopterin is a non-specific marker of the activation of cell-mediated immunity. "( Serum neopterin as an objective marker of psoriatic disease activity.
Catasús, M; Creus, L; Sánchez-Regaña, M; Umbert, P, 2000
)
"Neopterin is a simple, reliable and sensitive parameter of cell-mediated immunity, suitable for early diagnosis of viral, autoimmune and transplantant rejection diseases."( [Serum neopterin levels in oncology patients in intensive care].
Kausitz, J; Misianik, J; Setvak, D; Zahorec, R, 2000
)
"Neopterin is a soluble immune marker which was found to be a useful indicator for immune activation processes in humans, e.g."( Neopterin production in SCID mice injected with human peripheral blood mononuclear cells.
Amadori, A; Chieco-Bianchi, L; Diez-Ruiz, A; Fuchs, D; Veronesi, A; Wirleitner, B, 2001
)
"Neopterin is a marker associated with cell-mediated immunity. "( Neopterin measurement in clinical diagnosis.
Berdowska, A; Zwirska-Korczala, K, 2001
)
"Neopterin (NEOP) is a metabolite derived from guanosine triphosphate with the production and release of NEOP being induced in monocytes and macrophages by cytokines such as interferon-gamma (IFN-gamma)."( Serum neopterin monitoring and vitamin E-modified, regenerated hemodialyzer membrane influence on biocompatibility.
Hirao, Y; Kimura, S; Kitauchi, T; Ozono, S; Uemura, H; Yoneda, T; Yoshida, K, 2002
)
"Neopterin is a sensitive marker of the cellular immune response."( Immune monitoring in organ transplantation using neopterin.
Grebe, SO; Mueller, TF, 2002
)
"Neopterin is a by-product of guanosine triphosphate metabolism and is produced by macrophages in response to lymphocytic activation. "( Elevated neopterin levels in Guillain-Barré syndrome. Further evidence of immune activation.
Bansil, S; Cook, SD; Mithen, FA; Rohowsky-Kochan, C; Singhal, BS, 1992
)
"Neopterin is a biochemical marker of cellular mediated immune reactions and may be used in elucidating the cause of acute renal failure. "( [The level of neopterin in the plasma of patients with acute kidney failure during treatment with continuous arteriovenous hemofiltration].
Ametov, AS; Ipat'eva, EI; Kazakov, IV; Timokhov, VS; Toritsina, LK,
)
"Neopterin is an indirect marker of gamma interferon deliberation and may give some new information on the role of APC in CNS."( [Intrathecal production of neopterin in meningitis in childhood].
Koelfen, W; Korinthenberg, R; Teuber, J,
)
"Neopterin is a pyrazino-pyrimidine compound which is biosynthesized by macrophages. "( [Blood levels of neopterin in patients with liver cirrhosis].
Antoniello, S; Auletta, M; Bizzarro, A; Cacciatore, L; De Bellis, A; Di Martino, G; Russo, M,
)
"Neopterin is a metabolite of guanosine-triphosphate, released in vitro by macrophages under the control of gamma-interferon and described as a marker of T cell activation in vivo. "( Urinary neopterin in pulmonary sarcoidosis. Relationship to clinical and biologic assessment of the disease.
Auzeby, A; Barbosa, ML; Battesti, JP; Choudat, D; Lacronique, J; Marsac, J; Soler, P; Touitou, Y; Traore, BM; Valeyre, D, 1989
)
"Neopterin is thought to be an in-vitro indicator of activation of the immune system."( Possible uses of urinary neopterin and biopterin measurement.
Rabinoff, M, 1989
)
"Neopterin is an intermediate purine metabolite which can be determined in serum and has been shown to be elevated in processes that stimulate cell mediated immunity. "( [Predictive value of neopterin in boutonneuse fever].
Aramburu, J; Davins, J; Farré, J; Manterola, JM; Rey-Joly, C; Sabriá, M; Soriano, V, 1989
)
"Neopterin is a pyrazino-pyrimidine compound which is biosynthesized by macrophages. "( Serum neopterin levels in liver cirrhosis.
Antoniello, S; Auletta, M; Bizzarro, A; Cacciatore, L; De Bellis, A; Dell'Aquila, A; Magri, P; Russo, M; Russo, P,
)
"Neopterin is a low molecular weight product released by human macrophages upon stimulation with interferon gamma."( Neopterin levels in long-term hemodialysis.
Fuchs, D; Hausen, A; Reibnegger, G; von Dittrich, P; Wachter, H; Werner, ER, 1988
)
"Neopterin in CSF is a valuable marker of acute cellular immune response."( Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis.
Eneroth, P; Fredrikson, S; Link, H, 1987
)
"Neopterin is a marker for activation of cellular immunity. "( Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis.
Egg, D; Fuchs, D; Günther, R; Hausen, A; Reibnegger, G; Wachter, H; Werner, ER, 1986
)

Effects

Neopterin has been measured in many autoimmune diseases and was reported as a marker of cellular immunity activation in rheumatoid asthritis (RA) High neopterin levels have been accepted as strong indicators for the clinical severity of some diseases.

ExcerptReference
"Neopterin has a short half-life and was useful for monitoring inflammation activity in a patient with relapsing-remitting encephalitis. "( Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation.
Brilot, F; Dale, RC; Earl, J; Fagan, E, 2009
)
"Neopterin has been considered as an important marker of cellular inflammation. "( Neopterin: An immune biomarker of coronary artery disease and its association with other CAD markers.
Alama, MN; Almehdar, HA; Alzahrani, AS; Damanhouri, GA; Firoz, CK; Jabir, NR; Kamal, MA; Khan, W; Tabrez, S, 2015
)
"Neopterin has been measured in many autoimmune diseases and was reported as a marker of cellular immunity activation in rheumatoid asthritis (RA). "( Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients.
Ashmawy, I; El-Lebedy, D; Hussein, J; Mohammed, AM, 2017
)
"High neopterin levels have been accepted as strong indicators for the clinical severity of some diseases."( The association between neopterin and acetaminophen-induced nephrotoxicity.
Agilli, M; Akgul, OE; Aydin, FN; Aydin, I; Bilgi, C; Bilgic, S; Cakir, E; Cayci, T; Erbil, KM; Ersoz, N; Guven, A; Kurt, YG; Onguru, O; Turker, T; Yaman, H, 2010
)
"Neopterin has been shown to be even more sensitive when measured locally, e.g."( Biliary neopterin for differentiation between liver allograft rejection and viral graft infection.
Aichberger, C; Königsrainer, A; Margreiter, R; Reibnegger, G; Wachter, H; Weiss, G, 1992
)
"Neopterin production has been proposed as a marker of biological response in the clinical administration of a number of cytokines."( Increased systemic, but not regional, neopterin production following intraperitoneal administration of interleukin-2 and lack of effect of pterins upon the lymphokine-activated killer cell phenomenon.
Belinson, JL; Bigelow, JC; Hacker, MP; Moore, AL; Roberts, JD; Stewart, JA, 1994
)
"Neopterin has been determined in blood as a marker of cellular immune system activation. "( [Cerebrospinal fluid neopterin levels in children with neurologic diseases].
Nakazawa, T, 1996
)
"Neopterin has been suggested as a marker for the activation of macrophages, as indicated in several malignant tumors. "( [Liberation of neopterin after lung resecting interventions with and without bronchial carcinoma].
Brückner, UB; Gebhard, F; Lenz, J, 1996
)
"Neopterin has been recognized as a valid marker for cellular immune activation. "( Levels of serum neopterin are increased in pancreatic cancer patients and correlate with the prognosis.
Beger, HG; Birk, D; Gansauge, F; Gansauge, S; Schwarz, A, 1999
)
"The neopterin ELISA kit has been used in routine laboratory testing of blood donations in a blood bank."( Evaluation of a new simple and rapid enzyme-linked immunosorbent assay kit for neopterin determination.
Bertsch, T; Gerstner, L; Kozák, I; Krüger, C; Tatzber, F; Thiemann, F; Westermann, J, 2000
)
"Neopterin has been previously shown to be a non-specific but sensitive marker for immunologic activity."( Low serial serum neopterin does not predict low risk for chronic renal graft rejection.
Arbeiter, K; Aufricht, C; Balzar, E; Bidmon, B; Müller, T; Orgler, A; Ruffingshofer, D, 2001
)
"Neopterin serum levels have been measured in 37 patients diagnosed of boutonneuse mediterranean fever."( [Predictive value of neopterin in boutonneuse fever].
Aramburu, J; Davins, J; Farré, J; Manterola, JM; Rey-Joly, C; Sabriá, M; Soriano, V, 1989
)

Actions

Neopterin levels were lower in patients receiving clarithromycin. Neopterin likely plays a role in the occurrence and development of athermanous plaque and can serve as a useful biomarker of vulnerable plaques.

ExcerptReference
"Neopterin levels were lower in patients receiving clarithromycin."( Serum levels of neopterin during antimicrobial treatment for Mycobacterium ulcerans infection.
Abass, KM; de Zeeuw, J; Duggirala, S; Nienhuis, WA; Omansen, TF; Stienstra, Y; Tuah, W; van der Werf, TS, 2013
)
"Neopterin likely plays a role in the occurrence and development of athermanous plaque and can serve as a useful biomarker of vulnerable plaques."( Relationship between serum neopterin levels and coronary heart disease.
Li, YD; Liu, ZY, 2013
)
"Neopterin was lower in subjects using statins (n = 66) compared to those not taking statins (median (range): 6.65 (4.1-18.3) vs."( HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease.
Fuchs, D; Reinhart, WH; Walter, RB; Walter, TR; Weiss, G, 2003
)
"Neopterin plays an important role in the malignant disease diagnostics. "( Urinary neopterin quantification by reverse-phase high-performance liquid chromatography with ultraviolet detection.
Arita, DY; Casarini, DE; de Castro, MR; Di Marco, GS; Pereira, AB; Teixeira, LC, 2004
)
"Neopterin values were lower among current smokers than among nonsmokers (4.32 vs 5.16 nmol/L) and were higher among users of antihistamines (5.46 among users vs 4.65 nmol/L among nonusers)."( Factors influencing serum neopterin and beta 2-microglobulin levels in a healthy diverse population.
Blattner, WA; Brown, LM; Diamondstone, LS; Fuchs, D; Kurman, CC; Maloney, E; Nelson, DL; Tollerud, DJ; Wachter, H, 1994
)
"Neopterin does increase significantly in cases of transplant rejection but shows greater response to viral infection."( New markers in serum for lymphocyte activation for predicting allograft rejection. Neopterin and soluble interleukin-2 receptor.
Carlson, IH, 1992
)

Treatment

Neopterin treatment induced a decrease in serum erythropoietin concentrations in young mice but not in aged mice. Neopterin pretreatment (0th h) and control group concentrations were determined as 14.44 ± 0.30 (ng/mL) and 3.63 ¬0.29 (NG/mL), respectively.

ExcerptReference
"Neopterin pretreatment (0th h) and control group concentrations were determined as 14.44 ± 0.30 (ng/mL) and 3.63 ± 0.29 (ng/mL), respectively (p < 0.001)."( Neopterin, procalcitonin, clinical biochemistry, and hematology in calves with neonatal sepsis.
Akyüz, E; Gökce, G, 2021
)
"Neopterin treatment induced a decrease in serum erythropoietin concentrations in young mice but not in aged mice."( Neopterin, inflammation-associated product, prolongs erythropoiesis suppression in aged SAMP1 mice due to senescent stromal-cell impairment.
Aisaki, K; Aizawa, S; Harada, T; Hirabayashi, Y; Inoue, T; Kanno, J; Oshima, H; Tsuboi, I; Yamashita, A, 2012
)

Toxicity

ExcerptReference
" No severe adverse side-effects occurred."( Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.
Bartholeyns, J; Bohbot, A; Dumont, S; Eber, M; Faradji, A; Lallot, C; Poindron, P; Roeslin, N; Schmitt-Goguel, M; Wiesel, ML, 1991
)
" Low doses of alpha-IFN should be considered for treatment of HCL patients who develop toxic side effects and for primary treatment of HCL patients with severe cytopenia."( Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients.
Abbrederis, K; Aulitzky, W; De Pauw, B; Gastl, G; Lang, A; Nerl, C; Thaler, J; Tilg, H; von Lüttichau, I; Werter, M, 1989
)
"05), although these two adverse events occurred independently."( Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis.
Ellner, JJ; Helfand, MS; Johnson, JL; Mugerwa, RD; Okwera, A; Vjecha, M; Wallis, RS; Whalen, CC, 1996
)
" coli) by these toxic agents and its modulation by neopterin and 7,8-dihydroneopterin."( Neopterin derivatives modulate toxicity of reactive species on Escherichia coli.
Fuchs, D; Wede, I; Widner, B, 1999
)
" In conclusion, this study shows that pulmonary administration of human IFN-beta1a is safe and that the pulmonary route of administration is a possible alternate route for the systemic delivery of IFN-beta1a."( Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosing.
Gillette, N; Green, J; Lane, J; Martin, PL; Niggemann, B; Rogge, M; Vaidyanathan, S, 2002
)
"Application-site disorders are well-known adverse events (AEs) associated with subcutaneous (s."( Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation.
Bertolino, M; Brearley, C; Jaber, A; Priestley, A; Seiberling, M, 2007
)
" Flu-like symptoms were a commonly reported adverse event."( A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
Baker, DP; Crossman, M; Davar, G; Glick, G; Gronke, RS; Hitchman, S; Hu, X; Liu, S; Miller, L; Nestorov, I; Richman, S; Rogge, M; Subramanyam, M; Zhu, Y, 2012
)
" This study evaluated the safe and effective use of Avonex Pen™ (prefilled pen), a single use autoinjector, for intramuscular delivery of interferon beta-1a (IM IFNβ-1a, Avonex) in MS patients."( An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Deykin, A; Fox, E; Grainger, W; Liu, S; Phillips, JT; Tuccillo, D, 2011
)
" Adverse events were monitored throughout."( An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Deykin, A; Fox, E; Grainger, W; Liu, S; Phillips, JT; Tuccillo, D, 2011
)
"The prefilled pen is a safe and effective device for administration of IM IFNβ-1a and represents an alternative method for self-injection for MS patients using this therapy."( An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Deykin, A; Fox, E; Grainger, W; Liu, S; Phillips, JT; Tuccillo, D, 2011
)
"Although adverse health effects produced by lead (Pb) have long been recognized, studies regarding the immunotoxic effects of occupational exposure report conflicting results."( Assessment of immunotoxicity parameters in individuals occupationally exposed to lead.
Fuchs, D; García-Lestón, J; Laffon, B; Mayan, O; Méndez, J; Moreira, AO; Pásaro, E; Roma-Torres, J; Schroecksnadel, S; Teixeira, JP, 2012
)
" Exposure to PQ at toxic doses can result in fatal acute lung injury."( Poly-ADP-ribose polymerase inhibition provides protection against lung injury in a rat paraquat toxicity model.
Altinel, O; Altinel, S; Ates, K; Istanbulluoglu, H; Karslioglu, Y; Korkmaz, A; Ogur, R; Topal, T; Toygar, M; Tuncer, SK; Uysal, B, 2016
)

Pharmacokinetics

The study used a new formulation of interferon-α-2a (SR-IFN-α) to quantify the magnitude and saturation of neopterin production over time in healthy volunteers. Plasma concentrations of IFN-beta were determined and biphasic nepterin concentrations were used as the pharmacodynamic (PD) endpoint.

ExcerptReference
"Interferon therapies suffer from a relatively short half-life of the products in circulation."( Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
Baker, DP; Chakraborty, A; Gill, A; Green, M; Hochman, PS; LePage, DJ; Martin, P; Pepinsky, RB; Vaidyanathan, S; Whalley, E, 2001
)
" Plasma concentrations of IFN-beta were determined and biphasic neopterin concentrations were used as the pharmacodynamic (PD) endpoint."( Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys.
Efthymiopoulos, C; Jusko, WJ; Mager, DE; Munafo, A; Neuteboom, B, 2003
)
"Interferon (IFN) alpha conjugation to polyethylene glycol (PEG) results in a better pharmacokinetic profile and efficacy."( Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
Bello-Rivero, I; Bermúdez-Badell, CH; Castro-Odio, FR; Cruz-Díaz, M; Díaz-Machado, A; Ferrero-Bibilonia, J; García-García, I; González-Delgado, CA; López-Saura, PA; Nodarse-Cuní, H; Páez-Meireles, R; Pérez-Pérez, O; Valenzuela-Silva, CM, 2010
)
" Other clinical and laboratory variables were used as pharmacodynamic and safety criteria."( Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
Bello-Rivero, I; Bermúdez-Badell, CH; Castro-Odio, FR; Cruz-Díaz, M; Díaz-Machado, A; Ferrero-Bibilonia, J; García-García, I; González-Delgado, CA; López-Saura, PA; Nodarse-Cuní, H; Páez-Meireles, R; Pérez-Pérez, O; Valenzuela-Silva, CM, 2010
)
"The pharmacokinetic comparison by EIA yielded a high similitude between the formulations."( Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
Bello-Rivero, I; Bermúdez-Badell, CH; Castro-Odio, FR; Cruz-Díaz, M; Díaz-Machado, A; Ferrero-Bibilonia, J; García-García, I; González-Delgado, CA; López-Saura, PA; Nodarse-Cuní, H; Páez-Meireles, R; Pérez-Pérez, O; Valenzuela-Silva, CM, 2010
)
" All of them received intramuscularly a single high dose (23 × 10(6) IU) of a novel synergistic IFN mixture (HeberPAG) for pharmacokinetic and pharmacodynamic studies."( Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
Alfonso-Alvarado, C; Bello-Rivero, I; Cabrera-Placeres, M; Carballo-Treto, TI; Castro-Basart, N; Collazo-Caballero, SE; Cruz-Ramírez, A; Duncan-Roberts, Y; García-García, I; García-Iglesias, E; García-Vega, Y; Izquierdo-Toledo, Y; Santely-Pravia, EE; Soto-Matos, J; Tuero-Iglesias, AD; Vázquez-Blomquist, D, 2012
)
"The pharmacokinetic evaluation by EIA yielded a similar pattern for both IFNs that are also in agreement with the well-known described profiles for these molecules when these are administered separately."( Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
Alfonso-Alvarado, C; Bello-Rivero, I; Cabrera-Placeres, M; Carballo-Treto, TI; Castro-Basart, N; Collazo-Caballero, SE; Cruz-Ramírez, A; Duncan-Roberts, Y; García-García, I; García-Iglesias, E; García-Vega, Y; Izquierdo-Toledo, Y; Santely-Pravia, EE; Soto-Matos, J; Tuero-Iglesias, AD; Vázquez-Blomquist, D, 2012
)
"HeberPAG possesses improved pharmacodynamic properties that may be very useful in the oncologic setting."( Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
Alfonso-Alvarado, C; Bello-Rivero, I; Cabrera-Placeres, M; Carballo-Treto, TI; Castro-Basart, N; Collazo-Caballero, SE; Cruz-Ramírez, A; Duncan-Roberts, Y; García-García, I; García-Iglesias, E; García-Vega, Y; Izquierdo-Toledo, Y; Santely-Pravia, EE; Soto-Matos, J; Tuero-Iglesias, AD; Vázquez-Blomquist, D, 2012
)
"A single-dose study was conducted to characterize the safety, pharmacokinetic, immunogenicity, and pharmacodynamic activity of highly purified Staphylococcal protein A (SPA), a native bacterial protein with immune-modulatory activity."( Safety, pharmacokinetic, immunogenicity, and pharmacodynamic responses in healthy volunteers following a single intravenous injection of purified staphylococcal protein A.
Ballow, C; Bernton, E; Haughey, D; Leh, A; Slentz-Kesler, K; Yan, J, 2013
)
"In this study, we developed a pharmacokinetic (PK)- pharmacodynamic (PD) model of a new sustained release formulation of interferon-α-2a (SR-IFN-α) using the blood concentration of IFN-α and neopterin in order to quantify the magnitude and saturation of neopterin production over time in healthy volunteers."( Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.
Han, S; Hong, T; Jeon, S; Juhn, JH; Lee, J; Paek, J; Yim, DS, 2013
)
" These studies established a no-observable-adverse-effect level (NOAEL) for up to 12 weekly doses of SPA, as well as toxicokinetic profiles for SPA, evaluation of antiproduct antibodies and biomarkers to better characterize the pharmacodynamic response to SPA."( Studies of the safety, pharmacokinetics and immunogenicity of repeated doses of intravenous staphylococcal protein A in cynomolgus monkeys.
Bernton, E; Haughey, D, 2014
)
" The results showed a fractional increase in area-under-the-concentration-time curve (AUC [30-53%]) and peak serum concentration (Cmax [26-42%]) in subjects with mild, moderate, and severe renal impairment, versus healthy subjects; AUC and Cmax were similar for healthy subjects and end-stage-renal-disease patients receiving hemodialysis."( Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Goyal, J; Hu, X; Hung, S; Marbury, T; Matson, M; Nestorov, I; Seddighzadeh, A; Smith, W; Stecher, S; Zhu, Y, 2015
)
"5 days post-dosing, with a mono-phasic decline and a median half-life of approximately 2-3 days."( Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
Cui, Y; Deykin, A; Hu, X; Hung, S; Nestorov, I; White, J; Zhu, Y, 2015
)
" A pharmacokinetic and pharmacodynamic comparison of PEG-IFN-SA and peginterferon-α-2a in healthy subjects was evaluated."( A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
Cai, YM; Gou, ZP; Li, MP; Luo, H; Wang, Y; Xu, N; Zheng, L, 2015
)
"The US Food and Drug Administration (FDA) has taken steps to bring efficiency to the development of biosimilars, including establishing guidance for the use of pharmacokinetic and pharmacodynamic (PD) similarity study data without a comparative clinical study with efficacy end point(s)."( Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development - (III) A Randomized Trial with Interferon Beta-1a Products.
DePalma, R; Florian, J; Gershuny, V; Hazel, A; Hsiao, CH; Hyland, PL; Matta, MK; Prentice, K; Sanabria, C; Schrieber, SJ; Shah, A; Sheikhy, M; Strauss, DG; Sun, Q; Vegesna, G; Wang, YM; Weaver, JL, 2023
)

Compound-Compound Interactions

Neopterin secretion was also synergistically enhanced in AML blasts by the action of 1,25(OH)2D3 in combination with IFN but not GM-CSF. Neopterin was enhanced without concomitant evidence of phenotypic maturation.

ExcerptReference
"We have performed a phase IB study of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose (poly-ICLC) in combination with interleukin 2 (IL-2) in 25 patients with a variety of cancers."( Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.
Alvord, WG; Ewel, CH; Jones, MJ; Kopp, WC; Longo, DL; Pinsky, CM; Rossio, JL; Smith, JW; Steis, RG; Urba, WJ, 1992
)
" Neopterin secretion was also synergistically enhanced in AML blasts by the action of 1,25(OH)2D3 in combination with IFN but not GM-CSF; secretion was enhanced in AML blasts without concomitant evidence of phenotypic maturation."( Neopterin release by myeloid leukaemic cells can be synergistically augmented by 1,25-dihydroxyvitamin D3 in combination with gamma interferon or granulocyte-macrophage colony stimulating factor.
Coldwell, RD; Kelsey, SM; Makin, HL; Newland, AC; Syndercombe-Court, D, 1994
)
"IL-2 and IFN alpha-2a can be given with tolerable toxicities on an outpatient basis and shows significant activity in patients with metastatic RCC."( Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Conlon, KC; Creekmore, SP; Fenton, RG; Gause, BL; Holmlund, J; Janik, JE; Kopp, WC; Longo, DL; Sharfman, W; Smith, JW; Steis, RG; Sznol, M; Urba, WJ; VanderMolen, LA, 1996
)
"Levamisole combined with 5-fluorouracil (5-FU) was previously shown to significantly reduce tumor relapses and improve patient survival when given postoperatively in patients with resected stage III colon cancer."( Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer.
Krook, JE; Kugler, JW; Mahoney, MR; Morton, RF; O'Connell, MJ; Rayson, S; Rowland, KM; Sargent, DJ; Shepherd, L; Windschitl, HE, 2006
)
"Eight hundred seventy-eight patients who had undergone complete surgical resection of high-risk stage II/III colon cancer were stratified by known prognostic factors and randomized to receive 1 of 2 treatment regimens: standard-dose levamisole combined with 5-FU and leucovorin; or high-dose levamisole combined with the same chemotherapy."( Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer.
Krook, JE; Kugler, JW; Mahoney, MR; Morton, RF; O'Connell, MJ; Rayson, S; Rowland, KM; Sargent, DJ; Shepherd, L; Windschitl, HE, 2006
)
"It was not possible to improve the efficacy of surgical adjuvant chemotherapy for patients with high-risk colon cancer by giving levamisole at its maximum tolerated dose in combination with 5-FU and leucovorin."( Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer.
Krook, JE; Kugler, JW; Mahoney, MR; Morton, RF; O'Connell, MJ; Rayson, S; Rowland, KM; Sargent, DJ; Shepherd, L; Windschitl, HE, 2006
)
"This study investigated the efficacy of the integrated blood purification mode of early haemoperfusion (HP) combined with continuous venovenous haemodiafiltration (CVVHDF) in children with severe viral encephalitis, and evaluated the correlation of cerebrospinal fluid (CSF) neopterin (NPT) levels with prognosis."( The efficacy of haemoperfusion combined with continuous venovenous haemodiafiltration in the treatment of severe viral encephalitis in children.
Li, SJ; Liu, X; Ma, HK; Niu, WW; Shen, P; Wang, ZY; Zhan, XW; Zhao, JL, 2023
)
"Early HP combined with CVVHDF in the treatment of severe viral encephalitis in children may be a better approach than CVVHDF only for improving prognosis."( The efficacy of haemoperfusion combined with continuous venovenous haemodiafiltration in the treatment of severe viral encephalitis in children.
Li, SJ; Liu, X; Ma, HK; Niu, WW; Shen, P; Wang, ZY; Zhan, XW; Zhao, JL, 2023
)

Bioavailability

IFNβFc was well absorbed through the lung, displaying dose proportional increases in serum concentrations. It was biologically active, as shown by increases in plasma neopterin levels.

ExcerptReference
" However, the study cohort appeared to consist of two subpopulations with markedly different bioavailability for a given DHEA dose."( An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease.
Dyner, TS; Galmarini, M; Geaga, J; Golub, A; Jacobson, MA; Lang, W; Masterson, J; Stites, D; Winger, E, 1993
)
" Bioavailability for the PEG IFN-beta-1a was similar to the unmodified protein for each of the extravascular routes examined."( Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
Baker, DP; Chakraborty, A; Gill, A; Green, M; Hochman, PS; LePage, DJ; Martin, P; Pepinsky, RB; Vaidyanathan, S; Whalley, E, 2001
)
"Safety and bioavailability of pulmonary delivered interferon-beta 1a (IFN-beta1a, AVONEX, Biogen, Inc."( Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosing.
Gillette, N; Green, J; Lane, J; Martin, PL; Niggemann, B; Rogge, M; Vaidyanathan, S, 2002
)
" This study set out to test the hypothesis that in vivo gene transfer of GTPCH I to endothelial cells could increase bioavailability of BH4, enhance biosynthesis of nitric oxide and thereby enhance endothelium-dependent relaxations mediated by nitric oxide."( In vivo expression and function of recombinant GTPCH I in the rabbit carotid artery.
Hynes, SO; Katusic, ZS; Kovesdi, I; O'Brien, T; Richardson, DM; Smith, LA, 2004
)
" The aims of the present study were to investigate the bioavailability (BA) of the test product (either absolute or relative to the innovator product) and to compare the extent of increase of neopterin concentration following administration of either product."( Bioequivalence of two subcutaneous pharmaceutical products of interferon beta la.
Carbonetto, C; Dabsys, S; Di Girolamo, G; Diez, RA; González, E; Kauffman, MA; Keller, G; Papouchado, M; Ramírez, A; Sterin-Prync, A; Vidal, A, 2008
)
" IFNβFc was well absorbed through the lung, displaying dose proportional increases in serum concentrations, and was biologically active, as shown by increases in plasma neopterin levels."( Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway.
Bitonti, A; Low, S; Lu, Q; Rakhe, S; Reidy, T; Sakorafas, P; Vallee, S; Walker, S, 2012
)

Dosage Studied

Serum neopterin dosage may provide a useful tool for monitoring the therapy (particularly with biological response modifiers) of haematological neoplasias. A dose-response effect was observed for serum beta 2-microglobulin, neopter in, and p78.

ExcerptReference
" The study was carried out through the dosage of the serum levels of neopterin, a substance produced by the macrophages and usable as a marker of their state of activation."( Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects.
Allegra, A; Aloisi, C; Buemi, M; Frisina, N, 1991
)
" The authors think that this dosage could represent a mean of discovery of professional cancers in high risk populations as well as an element in the supervision of anti-neoplastic treatments."( [Urinary neopterin: its value in the study of various neoplasms].
Mura, P; Piriou, A; Reiss, D; Tallineau, C, 1986
)
" There was no consistent dose-response correlation for any surrogate marker."( Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
Boucher, CA; Hill, A; Ingrand, D; Katlama, C; Kitchen, V; McBride, M; McDade, H; Tubiana, R; van Leeuwen, R; Weber, J, 1995
)
" Dose proportionality was evidenced neither by the serum DHEA nor by DHEA-S time-concentration curves for the three dosing groups."( An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease.
Dyner, TS; Galmarini, M; Geaga, J; Golub, A; Jacobson, MA; Lang, W; Masterson, J; Stites, D; Winger, E, 1993
)
"We suggest that serum neopterin dosage has prognostic value in staging and follow-up, and may provide a useful tool for monitoring the therapy (particularly with biological response modifiers) of haematological neoplasias."( Serum neopterin levels in haematological malignancies.
Caenazzo, A; Dazzi, F; Girolami, A; Pietrogrande, F; Sartori, D; Sgarabotto, D; Vattamattathil, KP,
)
"Interferon-gamma (IFN-gamma) is a potent monocyte/macrophage activating agent that in animal models exhibits a bell-shaped dose-response curve of immunomodulatory activity and antitumor efficacy."( Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.
Alvord, WG; Ewel, CH; Guyre, PM; Kopp, WC; Longo, DL; Main, C; Smith, JW; Steis, RG; Urba, WJ, 1993
)
" In contrast, serum neopterin levels did not increase above baseline levels until 12 hr after iv dosing and 24 hr after sc dosing."( Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin.
Chiang, J; Gloff, CA; Williams, GJ; Yoshizawa, CN, 1993
)
" The purpose of this study is to define the maximum-tolerated dosage (MTD) of IL-2 and interferon alfa-2a (IFN alpha-2a) that can be administered chronically on an outpatient basis."( Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Conlon, KC; Creekmore, SP; Fenton, RG; Gause, BL; Holmlund, J; Janik, JE; Kopp, WC; Longo, DL; Sharfman, W; Smith, JW; Steis, RG; Sznol, M; Urba, WJ; VanderMolen, LA, 1996
)
" This study was designed to evaluate the biologically active dosage of aerosolized lymphoblastoid IFN-alpha, in normal subjects and patients with chronic bronchitis, using serum 2'-5' oligoadenylate synthetase (OAS) as a marker of IFN-alpha activity."( Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
Alemanno, L; Ameglio, F; Bisetti, A; Casarini, M; Giosuè, S; Saltini, C, 1996
)
"Buspirone was given as a single high dose to six HIV-seropositive subjects, or as continuous medication with increasing dosage over 6 weeks to nine HIV-seropositive subjects, with CD4 T-cell counts of 150-300 x 10(6)/l."( Buspirone, a serotonin receptor agonist, increases CD4 T-cell counts and modulates the immune system in HIV-seropositive subjects.
Aabech, P; Afzelius, P; Benfield, T; Dybkjaer, E; Hofmann, B; Iversen, J; Kronborg, G; Nielsen, JO, 1996
)
" Dosage and administration of the drug over a 7-week period were performed according to the instructions given by the company."( Treatment of feline leukemia virus-infected cats with paramunity inducer.
Block, A; Ferk, G; Goldberg, M; Hartmann, K; Lutz, H; Vollmar, A, 1998
)
" IL-10 concentrations in peritoneal fluids were increased after treatment with rIFN-gamma and the higher rIL-2 dosing (group A) but not in those treated with rIFN-gamma and the lower rIL-2 dosing (group B)."( Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Atkinson, EN; Edwards, CL; Freedman, RS; Kavanagh, JJ; Kudelka, AP; Levy, L; Melichar, B; Nash, M; Patenia, R; Platsoucas, CD; Scott, W; Templin, S; Verschraegen, C; Zhang, HZ, 2000
)
" The same dosage and schedule was repeated for two additional courses."( A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
Fukui, I; Gohchi, A; Hazama, S; Ikeda, S; Kinouchi, T; Kiyohara, Y; Kotake, T; Ohhashi, Y; Ohnishi, K; Ohno, R; Oka, M; Saji, S; Shibata, M; Sugiyama, Y; Taguchi, T; Toge, T; Tsukagoshi, S; Yamaguchi, Y, 2000
)
" A dose-response relationship between blood levels of PCP and cellular and humoral immune parameters was established."( Association of elevated blood levels of pentachlorophenol (PCP) with cellular and humoral immunodeficiencies.
Bauer, K; Conradt, C; Daniel, V; Huber, W; Melk, A; Mytilineos, J; Opelz, G; Suesal, C,
)
" There was a significant increase in the incidence and severity of local skin reactions including erythema, vesicle formation, ulceration, and excoriation as the dosing frequency increased from three times a week to three times a day."( Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.
Brown, DR; Douglas, JM; Ferenczy, A; Fife, KH; Owens, ML; Smith, M, 2001
)
"In this study, the optimal dosage regimen was the approved three times a week regimen."( Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.
Brown, DR; Douglas, JM; Ferenczy, A; Fife, KH; Owens, ML; Smith, M, 2001
)
" In the rat, a more extensive set of dosing routes was investigated, including intraperitoneal, intratracheal, and oral administration."( Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
Baker, DP; Chakraborty, A; Gill, A; Green, M; Hochman, PS; LePage, DJ; Martin, P; Pepinsky, RB; Vaidyanathan, S; Whalley, E, 2001
)
" No subjects required dosage reductions, and the adverse event profile was similar for the placebo and betaINF1a groups."( Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis.
, 2001
)
" The primary objective of this study was to determine the safety and immunologic activity of repeated recombinant human IL-12 (rhIL-12) dosing in HIV-infected patients over a broad range of the HIV disease spectrum."( A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.
Chan, E; Fox, L; Jacobson, MA; Katzenstein, D; Kundu, S; Landay, A; Pollard, R; Roe, J; Schock, B; Spritzler, J, 2002
)
"rhIL-12 dosed twice weekly at < or = 100 ng/kg was well tolerated in HIV-infected patients and resulted in dose-related increases in serum neopterin (possibly reflecting the effect of some degree of IFNgamma induction)."( A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.
Chan, E; Fox, L; Jacobson, MA; Katzenstein, D; Kundu, S; Landay, A; Pollard, R; Roe, J; Schock, B; Spritzler, J, 2002
)
" dosing at various dose levels."( Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys.
Efthymiopoulos, C; Jusko, WJ; Mager, DE; Munafo, A; Neuteboom, B, 2003
)
" Positive correlations were found between IFN dosage or serum levels and sVCAM-I, neopterin, sTNF-RII and sIL-2R, between sVCAM-1, sIL-2R, TNF-alpha, sTNF-RII and neopterin, sICAM-I and sVCAM-1, sIL2-R and sTNF-RII, and, finally, between sIL2-R and sICAM-I."( Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature.
Amberger, M; Günaydin, I; Koch, S; Kötter, I; Rückwaldt, U; Stübiger, N; Vonthein, R; Zierhut, M,
)
" Locteron merits further clinical investigation as a hepatitis C therapy suitable for dosing once per 2 weeks."( Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
Bechet, AC; De Leede, LG; Humphries, JE; Spencer, DG; Van Hoogdalem, EJ; Verrijk, R, 2008
)
" With choosing of adequate tests, the perioperative redox homeostasis of the transplanted patients can be monitored and with dosing the antioxidants the uncontrolled forming of reactive oxygen metabolites can also be decreased and checked."( [Investigation of redox homeostasis in liver and renal transplant recipients].
Blázovics, A; Czabai, G; Dinya, E; Fehérvári, I; Gaál, I; Gerlei, Z; Görög, D; Járay, J; Máthé, Z; Nemes, B; Pallai, Z; Perner, F; Sárváry, E; Sulyok, B; Varga, M, 2008
)
" Two randomized, blinded phase I studies were conducted: a single-dose study (n = 60) comparing subcutaneous or intramuscular PEG-IFN beta-1a (63, 125, or 188 µg) with intramuscular unmodified IFN beta-1a 30 µg and a multiple-dose study (n = 69) comparing subcutaneous PEG-IFN beta-1a dosed once every 2 or 4 weeks with placebo."( A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
Baker, DP; Crossman, M; Davar, G; Glick, G; Gronke, RS; Hitchman, S; Hu, X; Liu, S; Miller, L; Nestorov, I; Richman, S; Rogge, M; Subramanyam, M; Zhu, Y, 2012
)
" The dose-response relation between CRP and B-6 vitamers at day 28 was nonlinear, with an increased steepness of slope at CRP >7 mg/L."( Association of plasma B-6 vitamers with systemic markers of inflammation before and after pyridoxine treatment in patients with stable angina pectoris.
Midttun, Ø; Nygård, O; Pedersen, ER; Ueland, PM; Ulvik, A, 2012
)
" In peripheral blood mononuclear cells, SPA dosing increased transcription of multiple genes regulated by type-1 interferons, and up-regulation of several of these genes correlated with the degree of lymphopenia seen 24 hours after dosing."( Safety, pharmacokinetic, immunogenicity, and pharmacodynamic responses in healthy volunteers following a single intravenous injection of purified staphylococcal protein A.
Ballow, C; Bernton, E; Haughey, D; Leh, A; Slentz-Kesler, K; Yan, J, 2013
)
" The saturable pattern of the neopterin response blurring the dose-response relationship of SR-IFN-α was addressed by introducing the concept of the EC50 increasing over time."( Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.
Han, S; Hong, T; Jeon, S; Juhn, JH; Lee, J; Paek, J; Yim, DS, 2013
)
" The transient decrease in ALC noted at 24 hr after dosing was similar to that seen in human Phase 1 trials."( Studies of the safety, pharmacokinetics and immunogenicity of repeated doses of intravenous staphylococcal protein A in cynomolgus monkeys.
Bernton, E; Haughey, D, 2014
)
"The PK profile of peginterferon beta-1a did not change over time or between dosing regimens."( Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
Cui, Y; Deykin, A; Hu, X; Hung, S; Nestorov, I; White, J; Zhu, Y, 2015
)
"These PK/PD profiles potentially explain the enhanced efficacy of dosing every 2 weeks in patients with RRMS."( Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
Cui, Y; Deykin, A; Hu, X; Hung, S; Nestorov, I; White, J; Zhu, Y, 2015
)
" However, orally administered colchicine along with prednisolone effectively ameliorated her symptoms, and prednisolone dosage was reduced again."( Serum cytokine profile in pediatric Sweet's syndrome: a case report.
Fujino, H; Sumimoto, SI; Takano, Y; Yachie, A, 2017
)
" The dose-response curves support that therapeutic doses were adequately sensitive to detect differences in both PD biomarkers for consideration in a PD similarity study design."( Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development - (III) A Randomized Trial with Interferon Beta-1a Products.
DePalma, R; Florian, J; Gershuny, V; Hazel, A; Hsiao, CH; Hyland, PL; Matta, MK; Prentice, K; Sanabria, C; Schrieber, SJ; Shah, A; Sheikhy, M; Strauss, DG; Sun, Q; Vegesna, G; Wang, YM; Weaver, JL, 2023
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,489)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990336 (13.50)18.7374
1990's869 (34.91)18.2507
2000's591 (23.74)29.6817
2010's543 (21.82)24.3611
2020's150 (6.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials214 (8.14%)5.53%
Reviews122 (4.64%)6.00%
Case Studies74 (2.82%)4.05%
Observational17 (0.65%)0.25%
Other2,201 (83.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]